These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8561988)

  • 1. Hydroxyurea and HIV-1 viraemia.
    Lafeuillade A; Pellegrino P; Poggi C; Profizi N; Thiebaut C
    AIDS; 1995 Nov; 9(11):1290-1. PubMed ID: 8561988
    [No Abstract]   [Full Text] [Related]  

  • 2. No therapeutic advantage from didanosine (ddI) and hydroxyurea versus ddI alone in patients with HIV infection.
    Simonelli C; Comar M; Zanussi S; De Paoli P; Tirelli U; Giacca M
    AIDS; 1997 Aug; 11(10):1299-300. PubMed ID: 9256953
    [No Abstract]   [Full Text] [Related]  

  • 3. Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.
    Clotet B; Ruiz L; Cabrera C; Ibáñez A; Cañadas MP; Sirera G; Romeu J; Vila J
    Antivir Ther; 1996 Aug; 1(3):189-93. PubMed ID: 11322253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study.
    Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher HC; Bernasconi E; Sudre P; Leduc D; Yerly S; Perrin LH; Hirschel B
    AIDS; 1998 May; 12(8):F71-7. PubMed ID: 9631134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.
    Lori F; Malykh AG; Foli A; Maserati R; De Antoni A; Minoli L; Padrini D; Degli Antoni A; Barchi E; Jessen H; Wainberg MA; Gallo RC; Lisziewicz J
    AIDS Res Hum Retroviruses; 1997 Nov; 13(16):1403-9. PubMed ID: 9359660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
    Lori F; Pollard RB; Whitman L; Bakare N; Blick G; Shalit P; Foli A; Peterson D; Tennenberg A; Schrader S; Rashbaum B; Farthing C; Herman D; Norris D; Greiger P; Frank I; Groff A; Lova L; Asmuth D; Lisziewicz J
    AIDS Res Hum Retroviruses; 2005 Apr; 21(4):263-72. PubMed ID: 15943568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.
    Foli A; Lori F; Maserati R; Tinelli C; Minoli L; Lisziewicz J
    Antivir Ther; 1997 Jan; 2(1):31-8. PubMed ID: 11322264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of hydroxyurea in heavily pretreated patients with HIV infection.
    Hermans P; De Wit S; Sommereijns B; O'Doherty E; Clumeck N
    Antivir Ther; 1999; 4 Suppl 3():19-22. PubMed ID: 16021867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral treatment.
    Boelaert JR; Sperber K
    Lancet; 1998 Oct; 352(9135):1224-5. PubMed ID: 9777866
    [No Abstract]   [Full Text] [Related]  

  • 10. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide.
    Vila J; Nugier F; Barguès G; Vallet T; Peyramond D; Hamedi-Sangsari F; Seigneurin JM
    Lancet; 1997 Aug; 350(9078):635-6. PubMed ID: 9288048
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.
    Zala C; Salomón H; Cahn P
    Antivir Ther; 1999; 4 Suppl 3():95-9. PubMed ID: 16021880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study.
    Yerly S; Rutschmann OT; Opravil M; Marchal F; Hirschel B; Perrin L
    J Infect Dis; 1999 Sep; 180(3):850-3. PubMed ID: 10438378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zidovudine plus didanosine in primary HIV-1 infection.
    Perrin L; Yerly S; Charvier A; Figueras G; Schockmel GA; Hirschel B
    Antivir Ther; 1997 Jan; 2(1):5-11. PubMed ID: 11322267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia.
    Simonelli C; Zanussi S; Comar M; Vaccher E; Giacca M; De Paoli P; Tirelli U
    AIDS; 1998 Jan; 12(1):112-3. PubMed ID: 9456263
    [No Abstract]   [Full Text] [Related]  

  • 16. Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy.
    Barreiro P; de Mendoza C; Soriano V; González-Lahoz J
    AIDS; 2000 Jan; 14(2):207-8. PubMed ID: 10708295
    [No Abstract]   [Full Text] [Related]  

  • 17. Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV infection.
    Cepeda JA; Wilks D
    AIDS; 2000 Feb; 14(3):332-3. PubMed ID: 10716516
    [No Abstract]   [Full Text] [Related]  

  • 18. Hydroxyurea continues to show promise.
    Santiago L
    GMHC Treat Issues; 1996 Feb; 10(2):9-11. PubMed ID: 11363387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
    Kojima E; Shirasaka T; Anderson BD; Chokekijchai S; Steinberg SM; Broder S; Yarchoan R; Mitsuya H
    J Infect Dis; 1995 May; 171(5):1152-8. PubMed ID: 7751690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea in the treatment of HIV-1.
    Gibbs MA; Sorensen SJ
    Ann Pharmacother; 2000 Jan; 34(1):89-93. PubMed ID: 10669190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.